Chapter 16 Cold Storage
SIXTEEN
“Cold Storage”
HALO
The cold hits like a wall.
Not the clean cold of a winter night or the sharp bite of mountain air.
This is industrial refrigeration—the kind that preserves meat, or pharmaceuticals, or biological assets classified as hazardous.
The air burns my lungs with every breath, sharp and sterile, carrying the faint chemical tang of preservation fluids and something else underneath.
Something organic. The smell of things that used to be alive.
Cassie is three steps ahead, her flashlight beam cutting through the darkness. She stopped at the threshold, waiting for me to catch up. Good instinct. A week ago, she would have charged in. Now she’s learning to read my movements, to anticipate the tactical rhythm.
Smart. She’s becoming a partner instead of a package.
“Clear,” I murmur, sweeping the space with my own light. The beam bounces off stainless steel surfaces and refracts through frost crystals suspended in the frozen air.
The room opens up before us, vast and clinical.
Rows of storage containers stretch into the shadows—metal cylinders with digital readouts glowing blue and green in the darkness, frost creeping up their sides like white fingers reaching for the lids.
Hundreds of them. Maybe more. The scale is staggering.
But the setup is wrong for distribution.
Not a weapons cache. Not a staging area for mass deployment.
A research lab. Development phase. Whatever they’re building here, it isn’t finished yet.
I move past her, keeping low, checking sight lines even though the facility shows every sign of evacuation.
Empty workstations. Overturned chairs. Equipment left running on standby, humming softly in the silence.
Old habits don’t care about evidence of abandonment. Old habits are why I’m still breathing.
The containers are labeled with serial numbers and batch codes. I photograph the nearest cluster, then crouch to examine the markings more closely.
BIOLOGICAL COMPUTATION COMPONENT
ORGANIC NEURAL TISSUE
PHASE THREE READY
The words don’t make sense. Biological computation. Organic neural tissue. I read them twice, waiting for meaning to click into place. It doesn’t.
“Small quantities,” I say. “Each container holds maybe a hundred units. This isn’t manufacturing capacity. It’s R&D.”
“So they’re still developing it? Whatever it is?” Cassie moves to the next row, her footsteps careful on the frost-slicked concrete. “Still trying to get it to work.”
“Looks like.”
The observation should be reassuring. Whatever nightmare Phoenix is planning, it’s not ready yet.
But the scale of the operation—the investment, the infrastructure, the clinical precision of every detail—tells a different story.
This isn’t a project that might fail. This is a project that’s being refined until it succeeds.
I move deeper into the lab. Workstations line the walls—microscopes with automated focusing systems, centrifuges still loaded with sample vials, equipment I can name but couldn’t operate without training.
Papers scattered across desks in patterns that suggest sudden departure rather than careful organization.
Coffee cups frozen solid, the liquid transformed into brown ice sculptures.
They left in a hurry. But not today. The frost on the mugs is old, the papers stiff with moisture that condensed and froze over time. Days, maybe weeks.
Something scared them so badly that they abandoned a multi-million-dollar research facility. And I don’t think it was us.
Cassie follows, her footsteps careful on the concrete floor.
She’s found her rhythm—staying close enough to communicate in whispers, far enough not to crowd my firing arc if I need to engage a threat.
Partnership in motion. The kind of coordination that used to take weeks to develop with trained operators.
She’s not trained. She’s just paying attention.
“Here.” She’s stopped at a filing cabinet, with drawers half-open, as if someone had started grabbing files and then given up. “Trial data.”
I cross to her position, keeping my light angled low to preserve our night vision.
The folders are thick, densely packed with charts and tables, and the kind of clinical shorthand that turns human suffering into spreadsheet entries.
Medical terminology mixed with statistical analysis.
The language of research divorced from the reality of what was being researched.
Meridian Pharmaceuticals - ML-273 Phase I Trial. Cancer Treatment Efficacy Study
“Cancer treatment,” Cassie reads, her voice carefully neutral. “That’s what they told the subjects.”
“That’s what they told everyone.” I flip through the pages, scanning for the methodology section. “Look at this. The formulation wasn’t targeting tumors. It was targeting neural tissue. Brain chemistry. Synaptic structures.”
“So the cancer treatment was a cover?”
“The cancer treatment was a lie.”
The trial data reads like a horror novel written in clinical notation. Each entry follows the same format—subject number, baseline assessment, treatment protocol, outcome. The outcomes are almost uniformly terrible.
Subject 7: Mortality. Neural hemorrhage. Time from treatment to expiration: 72 hours.
Subject 12: Mortality. Systemic rejection. Time from treatment to expiration: 96 hours.
Subject 19: Mortality. Cognitive collapse. Subject remained conscious but non-responsive for 48 hours prior to cardiac failure.
Subject 23: Mortality. Organ failure secondary to neural degradation. Time from treatment to expiration: 31 hours.
Row after row. Death after death. Failures marked in cold shorthand like they were discussing crop yields instead of human beings dying in confused agony while their brains turned against them.
My jaw tightens. The clinical detachment of it—the way they reduced suffering to data points—triggers something cold and violent in my chest. I’ve killed people.
I’ve watched people die. But there’s always been a reason, a justification, an enemy that needed stopping.
This is different. This is extermination dressed up as research. This is murder with footnotes.
“They were using cancer patients as test subjects,” Cassie says.
Her voice is steady, but the edge in it is unmistakable.
The lawyer processing evidence that should have been presented to a grand jury.
The human processing horrors that should have been prevented.
“People who were already sick. Already vulnerable.”
“Compromised immune systems.” I keep my own voice clinical.
Emotion doesn’t help here—but I can feel it pressing against the walls I’ve built around it, demanding acknowledgment.
“Less likely to reject the modification because their bodies were already suppressed from the cancer treatment. Less likely to be missed if they died because they were supposed to die anyway.”
“Jesus Christ.”
I keep reading. Force myself to absorb what I’m seeing even though every page makes me want to put my fist through the frozen wall.
Most entries follow the same grim pattern—subject number, procedure, mortality, cause of death.
Whatever they were trying to do, it wasn’t working.
Just leaving corpses and data points and grieving families who thought their loved ones died of cancer instead of experimental torture.
But some entries are different.
Subject 31: Conversion successful. Neural integration confirmed at 94% threshold. Cognitive function maintained. Subject reports heightened clarity of thought. Monitoring ongoing.
Subject 47: Conversion successful. Cognitive patterns altered within expected parameters. No adverse effects observed at 72-hour mark. Subject cleared for long-term observation.
Subject 58: Conversion successful. Subject reports no adverse effects. Integration appears stable. Transferred to Phase II monitoring protocol.
“Conversion.” The word sticks in my throat. “That word keeps coming up.”
“Conversion, to what?”
I don’t have an answer. The technical jargon is dense—synaptic modification protocols, neural pathway restructuring, cognitive integration frameworks. It reads like someone trying to rewrite the operating system of the human brain.
But the why isn’t here. Or if it is, I can’t decode it from the medical terminology.
“There’s more.” Cassie pulls another folder from the cabinet, this one thicker than the first, bound with a red classification band. “Dated six months after the initial trials.”
ML-273 Reformulation - Phase II Protocol
Bioavailability Enhancement Study
The newer files tell a different story. Same targets. But a refined approach—someone learned from all those deaths and adjusted the formula.
Improved delivery mechanism utilizing lipid nanoparticle carrier.
Bioavailability increased 340% over Phase I formulation.
Neural compatibility threshold reached in 67% of subjects (up from 12% in Phase I).
Mortality rate: 31% (down from 78% in Phase I).
Average time to confirmed conversion: 18 days (down from indeterminate in Phase I).
“They fixed it,” Cassie breathes, her voice catching on the word. “Or—made it work better.”
“Better is relative.” I photograph the pages, making sure to capture every notation. “Thirty-one percent mortality still means one in three people die. That’s not acceptable by any standard of medical ethics.”
“But Phoenix doesn’t care about medical ethics.”
“No.” I find the notation that confirms it, written in the margin in precise handwriting:
Acceptable casualty threshold achieved for critical mass projection. Recommend advancement to Phase III deployment planning.
Critical mass. Of what?